Flow cytometric analysis of CD4+ T cell re-activation following anti-PD1 immunotherapy in a transgenic mouse model
Sheriff, Lozan; Bending, David

DOI:
10.1016/j.xpro.2022.101161

License:
Creative Commons: Attribution (CC BY)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.
Protocol
Flow cytometric analysis of CD4+ T cell reactivation following anti-PD1 immunotherapy in a transgenic mouse model

This protocol uses the Tg4 Nr4a3-Tocky mouse model to recalibrate T cell activation thresholds and reveals the role that immune checkpoints play in controlling T cell activation. The example approach here uses flow cytometry to characterize quantitative and qualitative changes in splenic CD4⁺ T cells reactivated in the presence of anti-PD1 immunotherapy. The protocol is optimized for studying anti-PD1 pathway blockade only. The protocol is not compatible with cellular fixation, and T cells should be analyzed immediately after staining.

Lozan Sheriff, David Bending
d.a.bending@bham.ac.uk

Highlights
We employ the Tg4 Nr4a3-Tocky mouse model to alter thresholds for T cell activation in vivo
The protocol identifies responder T cells through re-expression of Nr4a3-Timer Blue
We reveal the T cell phenotypic changes that result from anti-PD1 immunotherapy
Flow cytometric analysis of CD4+ T cell reactivation following anti-PD1 immunotherapy in a transgenic mouse model

Lozan Sheriff1 and David Bending1,2,3,*

1Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK
2Technical contact
3Lead contact
*Correspondence: d.a.bending@bham.ac.uk
https://doi.org/10.1016/j.xpro.2022.101161

SUMMARY
This protocol uses the Tg4 Nr4a3-Tocky mouse model to recalibrate T cell activation thresholds and reveals the role that immune checkpoints play in controlling T cell activation. The example approach here uses flow cytometry to characterize quantitative and qualitative changes in splenic CD4+ T cells reactivated in the presence of anti-PD1 immunotherapy. The protocol is optimized for studying anti-PD1 pathway blockade only. The protocol is not compatible with cellular fixation, and T cells should be analyzed immediately after staining. For complete details on the use and execution of this protocol, please refer to Elliot et al. (2021).

BEFORE YOU BEGIN
Before starting with the protocol, F1 Nr4a3-Tocky Tg4 Tiger mouse strain should be generated. In addition, peptide, and high-quality in vivo grade blocking antibodies (shown to be functional in vivo) to PD1 and flow cytometry panels should all be titrated in advance. All animal experiments were approved by the local animal welfare and ethical review body and authorized under the authority of UK Home Office licenses P18A892E0A and PP3965017 (held by D.B.).

Prepare Tg4 Tiger Nr4a3-Tocky mouse line
The protocol uses the F1 generation from the breeding of Nr4a3-Tocky mice (C57BL6, I-A<sup>B</sup>) crossed with the Tg4 Tiger (II10-GFP) line, which is on the B10.PL background (Burton et al., 2014). Nr4a3-Tocky mice are NFAT-responsive distal TCR signaling reporter mice that express fluorescent timer (Timer) protein (Subach et al., 2009) under the control of Nr4a3 regulatory elements (Jennings et al., 2020). The Tg4 TCR transgenic is specific for a peptide derived from myelin basic protein (MBP) presented by the I-A<sup>B</sup> MHC Class II molecule (Figure 1). We maintain colonies of Nr4a3-Tocky mice as homozygous BAC transgenics (Jennings et al., 2021). Similarly, Tg4 II10-GFP are bred to homozygosity. This set up means no genotyping is required for the F1 generation as all will be “hemizygous” for transgenes. The protocol does not necessitate the presence of the II10-GFP transgene, and Tg4 mice can be crossed with Nr4a3-Tocky mice for use with the protocol. The protocol depends on the expression of Timer protein to capture the re-activation of T cells within the 4 h time frame. In theory, any TCR transgenic systems could be mated to the Nr4a3-Tocky line (e.g., OTII), although these have not been experimentally tested within our laboratory.

1. Breed Nr4a3-Tocky homozygous mice (Jennings et al., 2020) with homozygous Tg4 II10-GFP mice.
2. All mice within the F1 generation will be usable.

3. We recommend using mice at 5–6 weeks of age as, in our hands, inter-mouse experimental variance increases with age.

**CRITICAL:** Mice should be randomized for age and sex across experimental conditions. We suggest a minimum of 4–5 mice per experimental group. Troubleshooting 1

### Prepare 4Y-MBP peptide

We use an acetylated tyrosine at position 4 [4Y] variant of MBP (Ac-ASQYRPSQR). The native lysine at position 4 [4K] MBP (ASQKRPSQR) induces weak activation of T cells (Elliot et al., 2021). The [4Y] MBP variant has enhanced binding to I-AU compared to the [4Y] MBP variant (Fairchild et al., 1993), making it more potent in activating T cells in vivo.

4. Purchase 10 mg–50 mg of MBP (custom product from GL Biochem Shanghai, sequence Ac-ASQYRPSQR, ≥90% purity).

5. Upon arrival, reconstitute the powder in sterile dd H2O to a stock concentration of 4 mg/mL and freeze it in aliquots until use. We typically prepare 200 μL aliquots and freeze at −20°C.

**CRITICAL:** Avoid freeze/thaw cycles and always use fresh aliquots. Always keep peptides on ice when transporting.

### Prepare anti-PD1

Anti-PD1 preparation:

6. Purchase in vivo grade anti-PD1, clone 29F.1A12 (available from BioLegend or BioXcell) and isotype control (rat IgG2a). We use rat IgG2a (clone MAC219 (Forsyth et al., 2000))

7. Anti-PD1 and the isotype controls are stored in the fridge (4°C) until use.
The panel design has been optimized to minimize interference with the Timer-Blue channel (excitation 405 nm, detection 450/50 nm filters). We have previously shown that at physiological expression levels, GFP (excitation 488 nm detection 530/30 nm filters), Timer Blue and Timer Red (excitation 561 nm, detection 610/20 nm filters) show negligible compensation requirements (Jennings et al., 2021). A key compensation consideration is the overlap of PE-Cy7 and PE-Texas Red (Timer-Red) channels. We strongly recommend that for PE-Cy7 compensation, the same antibody is used for single color controls. Troubleshooting 2

### Suggested flow cytometer setup and panel

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Source</th>
<th>Clone</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat anti-mouse PD1 PE-Cy7</td>
<td>BioLegend</td>
<td>29F.1A12</td>
<td>1:200</td>
</tr>
<tr>
<td>Rat anti-mouse OX40 APC</td>
<td>BioLegend</td>
<td>OX86</td>
<td>1:200</td>
</tr>
<tr>
<td>Armenian hamster anti-human/mouse ICOS AF700</td>
<td>BioLegend</td>
<td>C398.4A</td>
<td>1:50</td>
</tr>
<tr>
<td>eFluor-780 fixable viability dye</td>
<td>eBioscience</td>
<td>NA</td>
<td>1:2000</td>
</tr>
<tr>
<td>Rat anti-mouse CD4 BUV737</td>
<td>BD Biosciences</td>
<td>GK1.5</td>
<td>1:200</td>
</tr>
<tr>
<td>Mouse anti-mouse TCR Vbeta8.1,8.2 BUV395</td>
<td>BD Biosciences</td>
<td>MRS-2</td>
<td>1:200</td>
</tr>
</tbody>
</table>

For further details regarding compensation matrix considerations and fluorochrome compatibility with Nr4a3-Timer Red, Nr4a3-Timer Blue and GFP please refer to (Jennings et al., 2021). Troubleshooting 3

### Example BD LSR Fortessa X20 cytometer set up

<table>
<thead>
<tr>
<th>Detector name</th>
<th>Laser (nm)</th>
<th>Filters (nm)</th>
<th>Fluorochrome</th>
<th>Voltage (volts)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC</td>
<td>488</td>
<td>530/30</td>
<td>GFP</td>
<td>403</td>
</tr>
<tr>
<td>BV421</td>
<td>405</td>
<td>540/50</td>
<td>Timer Blue</td>
<td>412</td>
</tr>
<tr>
<td>PE-Texas Red</td>
<td>561</td>
<td>610/20</td>
<td>Timer Red</td>
<td>610</td>
</tr>
<tr>
<td>PE-Cy7</td>
<td>561</td>
<td>795/71</td>
<td>PE-Cy7</td>
<td>521</td>
</tr>
<tr>
<td>APC</td>
<td>640</td>
<td>670/30</td>
<td>APC</td>
<td>580</td>
</tr>
<tr>
<td>APC-Alexa 700</td>
<td>640</td>
<td>730/45</td>
<td>AF700</td>
<td>530</td>
</tr>
<tr>
<td>APC-Cy7</td>
<td>640</td>
<td>780/60</td>
<td>eFluor 780</td>
<td>481</td>
</tr>
<tr>
<td>BUV395</td>
<td>355</td>
<td>379/28</td>
<td>BUV395</td>
<td>559</td>
</tr>
<tr>
<td>BUV737</td>
<td>355</td>
<td>740/35</td>
<td>BUV737</td>
<td>700</td>
</tr>
</tbody>
</table>

### Example compensation matrix (% overlap)

<table>
<thead>
<tr>
<th>GFP (FITC)</th>
<th>Blue (BV421)</th>
<th>Red (PE-Texas Red)</th>
<th>PE-Cy7</th>
<th>APC</th>
<th>AF700</th>
<th>APC-Cy7</th>
<th>BUV395</th>
<th>BUV737</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>0.1</td>
<td>0</td>
<td>0.2</td>
<td>1.7</td>
<td>100</td>
<td>0.4</td>
<td>3.7</td>
<td>0</td>
<td>3.3</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>3.3</td>
<td>3.7</td>
<td>100</td>
<td>11.5</td>
<td>0</td>
<td>12</td>
</tr>
<tr>
<td>0.7</td>
<td>0</td>
<td>0.4</td>
<td>23</td>
<td>3.2</td>
<td>12</td>
<td>100</td>
<td>0</td>
<td>13.5</td>
</tr>
<tr>
<td>0</td>
<td>0.2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.2</td>
<td>0.1</td>
<td>0.3</td>
<td>1.8</td>
<td>0.9</td>
<td>100</td>
</tr>
</tbody>
</table>

For further details regarding compensation matrix considerations and fluorochrome compatibility with Nr4a3-Timer Red, Nr4a3-Timer Blue and GFP please refer to (Jennings et al., 2021). Troubleshooting 3

### KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibodies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat anti-mouse CD4</td>
<td>BD Biosciences</td>
<td>Cat# 612761; RRID: AB_2870092</td>
</tr>
<tr>
<td>(clone GK1.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse anti-mouse TCR Vb8.1,8.2</td>
<td>BD Biosciences</td>
<td>Cat# 744335; RRID: AB_2742163</td>
</tr>
<tr>
<td>BUV395 (clone MRS-2, 1 in 200 dilution)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued on next page)
STEP-BY-STEP METHOD DETAILS

Primary immunization

△ Timing: 24 h

1. Primary immunization of mice with 80 μg [4Y] MBP
   a. Prepare [4Y] MBP at a concentration of 0.4 mg/mL in 1 x PBS, with 200 μL volume required per mouse, plus 10% extra as buffer. Keep on ice.
   b. Inject Tg4 Tiger Nr4a3-Tocky mice with 200 μL peptide (80 μg total dose) subcutaneously into the right flank using a 0.5 mL insulin needle and syringe.
   c. After injection of the peptide, remove the needle and gently pinch skin for 10 s to minimize peptide/PBS leakage.
   d. Leave mice for 24 h.

Θ CRITICAL: A bolus shape should form under the skin if injection is subcutaneous. If significant amounts of peptide/PBS solution leaks after injection (>5–10 μL) then that mouse should be excluded from the experiment.
Administration of anti-PD1 immunotherapy

△ Timing: 30–60 min

2. Preparation and injection of anti-PD1 antibodies
   a. Prepare anti-PD1 and isotype control antibodies at a concentration of 2.5 mg/mL in sterile 1× PBS. You will require 200 μL per mouse plus 10% excess volume.
   b. Inject 0.5 mg (200 μL) of anti-PD1 or isotype control i.p. 24 h after the primary immunization.
   c. Wait for 30 min.

Θ CRITICAL: It is crucial to allow a minimum of 30 minutes for the antibodies to distribute in the mouse before re-challenge with peptide. Troubleshooting 4

Peptide re-challenge of mice

△ Timing: 4 h

3. Rechallenge of mice with 8 μg [4Y] MBP
   a. Prepare [4Y] MBP at a concentration of 0.04 mg/mL in 1× PBS, with 200 μL volume required per mouse, plus 10% extra as buffer. Keep on ice.
   b. Inject Tg4 Tiger Nr4a3-Tocky mice with 200 μL peptide (8 μg total dose) subcutaneously into the left flank using a 0.5 mL insulin needle and syringe.
   c. After injection of the peptide, remove the needle and gently pinch skin to for 10 s to minimize peptide/ PBS leakage.
   d. Leave mice for 4 h.

Note: 8 μg is a recommended rechallenge dose. However, lowering or raising this dose will alter the proportion of responder T cells (see Figure 4 (Elliot et al., 2021))

Θ CRITICAL: A bolus shape should form under the skin if injection is subcutaneous. If significant amounts of peptide/PBS solution leaks after injection (>5–10 μL) then that mouse should be excluded from the experiment.

Spleen harvest and generation of splenocyte suspensions

△ Timing: 1–2 h

4. After 4 h peptide rechallenge, euthanize mice, and process spleen for flow cytometric staining
   a. Mice are euthanized and the whole spleen is removed intact from the Tg4 Nr4a3-Tocky mice. Ensure complete detachment of the pancreas and place it into a 1.5 mL Eppendorf tube containing 0.5 mL of 2% FBS/ PBS (v/v).
   b. Into a sterile 5 mL petri dish, place a 70 μm cell strainer and add the spleen and 1 mL of 2% FBS PBS buffer. (Alternatively, a strainer can be placed in a 50 mL Falcon tube for processing).
   c. Using the syringe plunger from a 5 mL syringe, gently force the spleen through the cell strainer.
   d. Using a P1000 pipette add 1 mL 2% FBS PBS buffer to wash the strainer.
   e. Filter the splenocyte solution back through the strainer by taking from suspension in the petri dish and pipetting back onto the strainer.
      i) Repeat this 8–10 times using P1000 pipette until suspension is homogenous.
   f. Transfer the splenocyte suspension from each mouse into individual 15 mL Falcon tubes.
   g. Wash strainer with 1 mL 2% FBS PBS and transfer this to the 15 mL Falcon tube.
   h. Centrifuge Falcon tube at 500 g for 5 min at 15°C–25°C.
i. Decant supernatant and proceed to perform red blood cell lysis by resuspending the cell pellet in 1 mL of RBC lysis buffer.

j. Incubate for 2 min on ice.

k. Top up falcon tube to 10 mL with cold 2% FBS PBS and centrifuge at 500 g for 5 min at 4°C.

l. Decant supernatant and resuspend splenocytes in 2 mL ice cold 2% FBS PBS.

m. Transfer 100 μL of splenocyte suspension (typically 2–5M splenocytes) to a 96 well U bottom plate for staining. Alternatively, cells can be stained in 5 mL FACS tubes.

**Flow cytometric staining**

△ Timing: 1 h

5. Flow cytometric staining (for 96 well plate staining)
   a. Centrifuge 96 well plate at 500 g for 3 min at 15°C–25°C.
   b. Prepare master mix of antibodies in 2% FBS PBS containing 1 in 2000 dilution of fixable viability dye eFluor780, as per table below.

   **Optional:** For splenocyte analysis we do not routinely perform Fc receptor block, however this can be included at this stage.

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Dilution</th>
<th>Volume to add to 1 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD1 PE-Cy7</td>
<td>1:200</td>
<td>5 μL</td>
</tr>
<tr>
<td>OX40 APC</td>
<td>1:200</td>
<td>5 μL</td>
</tr>
<tr>
<td>ICOS AF700</td>
<td>1:50</td>
<td>20 μL</td>
</tr>
<tr>
<td>CD4 BUV737</td>
<td>1:200</td>
<td>5 μL</td>
</tr>
<tr>
<td>TCR Vbeta8.1,8.2 BUV395</td>
<td>1:200</td>
<td>5 μL</td>
</tr>
</tbody>
</table>

   c. Stain samples in 25 μL of antibody master mix.

   ◊ CRITICAL: Remember to include compensation controls. Unstained splenocytes can be used for compensation of *Nr4a3*-Timer Red (PE-Texas Red channel) as per (Jennings et al., 2021). As stated previously, the staining panel design is optimized to not require compensation between *Nr4a3*-Timer Blue (BV421 channel), GFP (FITC channel) and the other channels. For tandem dyes like PE-Cy7 use the same antibody from the panel master mix. Typical cytometer settings, channels and compensation matrix are shown earlier for reference, suggested controls are listed below. NB Timer Blue and Timer Red are excited by different lasers (405 nm versus 561 nm) and emit in different ranges (Timer Blue ~ 450 nm, Timer Red ~ 610 nm) so compensation between these two channels is not necessary. **Troubleshooting 2**

<table>
<thead>
<tr>
<th>Channel name</th>
<th>Panel stain</th>
<th>Compensation control suggestion</th>
</tr>
</thead>
<tbody>
<tr>
<td>FITC</td>
<td>II10-GFP</td>
<td>GFP expressing splenocytes/comp beads</td>
</tr>
<tr>
<td>BV421</td>
<td><em>Nr4a3</em>-Timer Blue</td>
<td>Not usually required if following suggested panel design, but can use 4 h anti-CD3 stimulated <em>Nr4a3</em>-Tocky splenocytes</td>
</tr>
<tr>
<td>PE-Texas Red</td>
<td><em>Nr4a3</em>-Timer Red</td>
<td><em>Nr4a3</em>-Tocky splenocytes</td>
</tr>
<tr>
<td>PE-Cy7</td>
<td>PD1 PE-Cy7</td>
<td>PD1 PE-Cy7</td>
</tr>
<tr>
<td>APC</td>
<td>OX40 APC</td>
<td>Any APC antibody</td>
</tr>
<tr>
<td>APC-Alexa 700</td>
<td>ICOS AF700</td>
<td>Any AF700 antibody</td>
</tr>
<tr>
<td>APC-Cy7</td>
<td>eFluor 780 viability dye</td>
<td>eFluor 780 viability dye</td>
</tr>
<tr>
<td>BUV395</td>
<td>TCRVbeta8.1/8.2 BUV395</td>
<td>TCRVbetab8.1/8.2 BUV395</td>
</tr>
<tr>
<td>BUV737</td>
<td>CD4 BUV737</td>
<td>CD4 BUV737</td>
</tr>
</tbody>
</table>
d. Incubate plate at 4°C for 20 min.

e. Add 180 μL of ice cold 2% FBS PBS to each well and centrifuge plate at 500 g for 3 min at 15°C–25°C.

f. Decant supernatant and resuspend pellets in 150 μL 2% FBS PBS and transfer to 5 mL FACS tubes.

g. Wells can be rinsed with 150 μL 2% FBS PBS and combined in FACS tube to give a total volume of 300 μL for acquisition.

h. Keep cells on ice in dark and acquire data on flow cytometer within 2–4 h.

CRITICAL: Do not fix cells as this will result in loss of Nr4a3-Timer Blue fluorescence. Due to slow maturation of Timer protein from Blue to Red it is advised that data are acquired soon after completion of staining. Troubleshooting 5

EXPECTED OUTCOMES

Treatment with anti-PD1 will increase the proportion of T cells that re-activate in response to re-challenge with the 8-μg dose of peptide in comparison to isotype treated mice. These cells are defined as the percentage of CD4+ T cells that are Nr4a3-Timer Blue+Red+ (Figure 2). Furthermore, analysis of CD4+ Nr4a3-Timer Blue+Red+ T cells will reveal that the median level of Nr4a3-Timer Blue and OX40 will be higher in responder T cells in the anti-PD1 treated group compared to isotype treated mice (Elliot et al., 2021). In addition, Il10-GFP expression will be found within the Nr4a3-Timer Red fraction (Figure 3).

QUANTIFICATION AND STATISTICAL ANALYSIS

Flow cytometry gates to determine responder populations can be set by including a mouse that receives the primary immunization (80 μg [4Y] MBP) but only PBS on the secondary restimulation. Most T cells, after 24 h immunization with 80 μg [4Y] MBP, are Nr4a3-Timer Red+Blue+ (Figure 4). When a second immunization with 8 μg [4Y] MBP is performed a clear Blue+Red+ population is observable. These are the “responder” cells. Gating on this population will allow a comparison of the phenotype of responder cells between treatment groups.
As part of a quality control step, we include a fluorochrome conjugated anti-PD1 antibody of the same clone as the blocking antibody administered in vivo. This allows confirmation of successful i.p. injection and that PD1 is blocked (Figure 5). Where significant PD1 staining remains, this indicates inadequate blocking of PD1, and such mice should be excluded from further analysis.

LIMITATIONS
The protocol here is optimized for anti-PD1 immunotherapy but has been adapted for other immune checkpoints such as Lag3; however, for other receptors confirmation that the receptor and its ligand are expressed in the splenic environment would be required. Due to the mixed mouse background, generation of gene knockouts is not straightforward, and would require backcrossing onto the B10.PL background.

The protocol is specific for CD4+ T cells, but theoretically could be adapted to CD8+ T cells using a CD8+ TCR transgenic. However, for all analyses of responder T cells, the protocol is not compatible with fixation and intranuclear staining and samples need to be analyzed soon after completion of flow cytometric staining.

TROUBLESHOOTING
Problem 1
High variability between mice (steps 1–3).

Potential solution
High variability is often driven by inadequate randomization. We typically use mice 5–6 weeks of age with weights 18–24 g. We ensure mice are randomized based on sex and age, as both influence weight. As multiple injections are given over time, large variance in mice weight can give rise to wider ranges in responses. One way to circumvent this is to administer doses on a mg/kg basis. We base our 80-μg dose...
on an approximate mouse weight of 20 g. This equates to doses of 4 mg/kg for primary immunization and 0.4 mg/kg for re-challenge. For antibody, 0.5 mg would equate to 25 mg/kg.

**Problem 2**

Timer-Red channel shows a skewed distribution (step 5).

**Potential solution**

This is typically a result of over or under compensation of PE-Cy7 and Timer Red (PE-Texas Red channel). In our experience PE-Cy7 tandem dyes exhibit subtle differences in compensation between batches and brands. It is imperative to use the same PE-Cy7 antibody as in the panel (either using beads compensation, or staining of cells expressing the ligand).

**Problem 3**

Timer-Blue and Timer-Red channels show diagonal autofluorescence (step 5).

**Potential solution**

You can utilize a “dump” channel to remove noise. We recommend using the PerCP-Cy5.5 channel (excited by a 488 nm laser, with 710/50 nm filters) to remove cells showing signal in this channel.

**Problem 4**

Minimal effect of anti-PD1 on T cell reactivation (step 2c).

**Potential solution**

There are several potential reasons for this. (1) A key part of the protocol is the minimum 30-min gap between administration of the anti-PD1 antibody and re-challenge with [4Y] MBP. This gap can be extended to increase the time for maximal blockade of the pathway for antibodies with potential different distribution half-lives. (2) It is strongly recommended that receptor blockade is confirmed through counter staining for the marker of interest. In our hands, a non-response is almost always due to a failed i.p. injection as evidenced by high PD1 staining.

**Problem 5**

Minimal Timer-Blue detected (steps 3–5).
**Potential solution**
This could represent a failed subcutaneous injection of 8 ug [4Y] MBP, which would result in no re-stimulation of the T cells in vivo. Conversely, this can arise if cells are left overnight in the fridge or fixed, as Timer Blue will undergo slow maturation to the terminal Red form, resulting in loss of Blue signal. It is imperative that the experiment is planned so that flow cytometric analysis can occur soon after completion of staining.

**RESOURCE AVAILABILITY**

**Lead contact**
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Dr David Bending, d.a.bending@bham.ac.uk.

**Materials availability**
Nr4a3-Tocky mice are available under MTA from Dr Masahiro Ono (Imperial College London, UK).

**Data and code availability**
Data underlying this protocol are available from the lead contact upon reasonable request.

**ACKNOWLEDGMENTS**
This work is funded by the MRC (MR/V009052/1). The graphical abstract and Figure 1 were created using https://biorender.com.

**AUTHOR CONTRIBUTIONS**

**DECLARATION OF INTERESTS**
The authors declare no competing interests.
REFERENCES


